Wall Street analysts forecast that Steris PLC (NYSE:STE) will report $709.63 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Steris’ earnings, with the highest sales estimate coming in at $711.20 million and the lowest estimate coming in at $707.00 million. Steris posted sales of $681.19 million during the same quarter last year, which would indicate a positive year over year growth rate of 4.2%. The business is scheduled to announce its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Steris will report full year sales of $709.63 million for the current fiscal year, with estimates ranging from $2.61 billion to $2.62 billion. For the next financial year, analysts expect that the business will post sales of $2.73 billion per share, with estimates ranging from $2.73 billion to $2.74 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Steris.
Steris (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.05. The business had revenue of $661.90 million for the quarter, compared to the consensus estimate of $663.17 million. Steris had a return on equity of 11.57% and a net margin of 9.42%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.98 earnings per share.
In other Steris news, Director Richard Martin Steeves sold 58,953 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $91.00, for a total transaction of $5,364,723.00. Following the sale, the director now directly owns 9,362 shares of the company’s stock, valued at $851,942. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jacqueline B. Kosecoff sold 2,744 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $91.94, for a total value of $252,283.36. The disclosure for this sale can be found here. Insiders sold 68,415 shares of company stock worth $6,223,536 over the last quarter. 2.55% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in Steris by 3.4% during the fourth quarter. BlackRock Inc. now owns 7,184,409 shares of the medical equipment provider’s stock worth $628,419,000 after acquiring an additional 239,200 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its stake in Steris by 0.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,487,376 shares of the medical equipment provider’s stock worth $130,101,000 after acquiring an additional 11,742 shares during the last quarter. American Century Companies Inc. increased its stake in Steris by 14.6% during the fourth quarter. American Century Companies Inc. now owns 1,194,167 shares of the medical equipment provider’s stock worth $104,454,000 after acquiring an additional 152,346 shares during the last quarter. Wells Fargo & Company MN increased its stake in Steris by 6.6% during the fourth quarter. Wells Fargo & Company MN now owns 1,105,452 shares of the medical equipment provider’s stock worth $96,694,000 after acquiring an additional 68,881 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Steris by 4.9% during the third quarter. Bank of New York Mellon Corp now owns 1,017,810 shares of the medical equipment provider’s stock worth $89,974,000 after acquiring an additional 47,682 shares during the last quarter. 89.40% of the stock is currently owned by institutional investors.
Shares of Steris (NYSE:STE) opened at $95.85 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.82 and a quick ratio of 2.22. The company has a market capitalization of $8,077.54, a PE ratio of 33.63 and a beta of 1.17. Steris has a 52-week low of $67.55 and a 52-week high of $96.34.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a $0.31 dividend. This is an increase from Steris’s previous quarterly dividend of $0.21. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date is Tuesday, February 27th. Steris’s payout ratio is currently 43.51%.
WARNING: “$709.63 Million in Sales Expected for Steris PLC (STE) This Quarter” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/13/709-63-million-in-sales-expected-for-steris-plc-ste-this-quarter.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.